Viridian Therapeutics (VRDN) Stock Forecast & Price Target

Compare

1,456 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

VRDN Analyst Ratings

Strong Buy

17 Buy

0 Hold

0 Sell

Based on 17 analysts giving stock ratings to

Viridian

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

VRDN Stock 12 Month Forecast

Average Price Target

$41.70

▲(37.49% Upside)

Based on 17 Wall Street analysts offering 12 month price targets for Viridian Therapeutics in the last 3 months. The average price target is $41.70 with a high forecast of $61.00 and a low forecast of $14.15. The average price target represents a 37.49% change from the last price of $30.33.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","62":"$62","23.75":"$23.8","36.5":"$36.5","49.25":"$49.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":61,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$61.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$41.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.154844,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.15</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,23.75,36.5,49.25,62],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.12,33.41846153846154,35.71692307692308,38.01538461538462,40.31384615384616,42.612307692307695,44.91076923076923,47.20923076923077,49.50769230769231,51.80615384615385,54.104615384615386,56.403076923076924,58.70153846153846,{"y":61,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.12,31.933846153846154,32.74769230769231,33.56153846153846,34.37538461538462,35.18923076923077,36.003076923076925,36.816923076923075,37.63076923076923,38.44461538461539,39.25846153846154,40.072307692307696,40.886153846153846,{"y":41.7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.12,29.814988,28.509976,27.204964,25.899952,24.59494,23.289928,21.984916,20.679904,19.374892000000003,18.06988,16.764868,15.459856,{"y":14.154844,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19.17,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.38,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.53,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.56,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.97,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.47,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.41,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.14,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.27,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.63,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.45,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.12,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$61.00

Average Price Target$41.70

Lowest Price Target$14.15

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Michael Yee

UBS

$50

Buy

64.85%

Upside

Initiated

01/07/26

Viridian Therapeutics initiated with a Buy at UBSViridian Therapeutics initiated with a Buy at UBS

Rami Katkhuda

LifeSci Capital

$46

Buy

51.67%

Upside

Reiterated

01/06/26

Viridian Therapeutics: Advancing TED Pipeline, 2026 Catalysts, and New TSH Receptor Inhibitor Underpin Buy Rating

Douglas Tsao

H.C. Wainwright

$34

Buy

12.10%

Upside

Reiterated

01/06/26

Viridian Therapeutics: Building a Best-in-Class Thyroid Disease Franchise with Multiple Clinical Catalysts Supporting a Buy Rating

Serge Belanger

Needham

$42

Buy

38.48%

Upside

Reiterated

01/06/26

Viridian Therapeutics: 2026 Clinical and Regulatory Catalysts, Strong Balance Sheet Support Buy Rating on VRDN

Lachlan Hanbury Brown

William Blair

Buy

―

Reiterated

01/06/26

Viridian Therapeutics: Multiple 2026 Catalysts and Pipeline Momentum Underpin Buy Rating

Gregory Renza

Truist Financial

Buy

―

Reiterated

12/23/25

Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (NASDAQ: VRDN), MDxHealth (NASDAQ: MDXH) and RxSight (NASDAQ: RXST)

Joseph Thome

TD Cowen

Buy

―

Reiterated

12/22/25

Analysts Are Bullish on These Healthcare Stocks: Simulations Plus (SLP), Viridian Therapeutics (VRDN)

Laura Chico

Wedbush

$47

Buy

54.96%

Upside

Reiterated

12/22/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Viridian Therapeutics (NASDAQ: VRDN), Fortrea Holdings Inc. (NASDAQ: FTRE) and Cytokinetics (NASDAQ: CYTK)

Gavin Clark-Gartner

Evercore ISI

$41→$42

Buy

38.48%

Upside

Reiterated

12/18/25

Evercore ISI Reaffirms Their Buy Rating on Viridian Therapeutics (VRDN)

Leland Gershell

Oppenheimer

$36

Buy

18.69%

Upside

Reiterated

11/06/25

Oppenheimer Remains a Buy on Viridian Therapeutics (VRDN)

Richard Law CFA

Goldman Sachs

$30→$40

Buy

31.88%

Upside

Reiterated

11/06/25

Viridian Therapeutics price target raised to $40 from $30 at Goldman SachsViridian Therapeutics price target raised to $40 from $30 at Goldman Sachs

Lisa Walter

RBC Capital

$41→$45

Buy

48.37%

Upside

Reiterated

11/06/25

Viridian Therapeutics price target raised to $45 from $41 at RBC CapitalViridian Therapeutics price target raised to $45 from $41 at RBC Capital

Julian Harrison

BTIG

$61

Buy

101.12%

Upside

Reiterated

11/04/25

Viridian Therapeutics: Promising Future with Strategic Advancements and Financial Backing

Thomas Smith

Leerink Partners

Buy

―

Reiterated

10/21/25

Analysts Offer Insights on Healthcare Companies: Celcuity (NASDAQ: CELC) and Viridian Therapeutics (NASDAQ: VRDN)

David Martin PhD

Bloom Burton

$14.15

Buy

-53.33%

Downside

Reiterated

10/21/25

Analysts Are Bullish on Top Healthcare Stocks: Nurix Therapeutics (NRIX), Viridian Therapeutics (VRDN)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Michael Yee

UBS

$50

Buy

64.85%

Upside

Initiated

01/07/26

Viridian Therapeutics initiated with a Buy at UBSViridian Therapeutics initiated with a Buy at UBS

Rami Katkhuda

LifeSci Capital

$46

Buy

51.67%

Upside

Reiterated

01/06/26

Viridian Therapeutics: Advancing TED Pipeline, 2026 Catalysts, and New TSH Receptor Inhibitor Underpin Buy Rating

Douglas Tsao

H.C. Wainwright

$34

Buy

12.10%

Upside

Reiterated

01/06/26

Viridian Therapeutics: Building a Best-in-Class Thyroid Disease Franchise with Multiple Clinical Catalysts Supporting a Buy Rating

Serge Belanger

Needham

$42

Buy

38.48%

Upside

Reiterated

01/06/26

Viridian Therapeutics: 2026 Clinical and Regulatory Catalysts, Strong Balance Sheet Support Buy Rating on VRDN

Lachlan Hanbury Brown

William Blair

Buy

―

Reiterated

01/06/26

Viridian Therapeutics: Multiple 2026 Catalysts and Pipeline Momentum Underpin Buy Rating

Gregory Renza

Truist Financial

Buy

―

Reiterated

12/23/25

Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (NASDAQ: VRDN), MDxHealth (NASDAQ: MDXH) and RxSight (NASDAQ: RXST)

Joseph Thome

TD Cowen

Buy

―

Reiterated

12/22/25

Analysts Are Bullish on These Healthcare Stocks: Simulations Plus (SLP), Viridian Therapeutics (VRDN)

Laura Chico

Wedbush

$47

Buy

54.96%

Upside

Reiterated

12/22/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Viridian Therapeutics (NASDAQ: VRDN), Fortrea Holdings Inc. (NASDAQ: FTRE) and Cytokinetics (NASDAQ: CYTK)

Gavin Clark-Gartner

Evercore ISI

$41→$42

Buy

38.48%

Upside

Reiterated

12/18/25

Evercore ISI Reaffirms Their Buy Rating on Viridian Therapeutics (VRDN)

Leland Gershell

Oppenheimer

$36

Buy

18.69%

Upside

Reiterated

11/06/25

Oppenheimer Remains a Buy on Viridian Therapeutics (VRDN)

Richard Law CFA

Goldman Sachs

$30→$40

Buy

31.88%

Upside

Reiterated

11/06/25

Viridian Therapeutics price target raised to $40 from $30 at Goldman SachsViridian Therapeutics price target raised to $40 from $30 at Goldman Sachs

Lisa Walter

RBC Capital

$41→$45

Buy

48.37%

Upside

Reiterated

11/06/25

Viridian Therapeutics price target raised to $45 from $41 at RBC CapitalViridian Therapeutics price target raised to $45 from $41 at RBC Capital

Julian Harrison

BTIG

$61

Buy

101.12%

Upside

Reiterated

11/04/25

Viridian Therapeutics: Promising Future with Strategic Advancements and Financial Backing

Thomas Smith

Leerink Partners

Buy

―

Reiterated

10/21/25

Analysts Offer Insights on Healthcare Companies: Celcuity (NASDAQ: CELC) and Viridian Therapeutics (NASDAQ: VRDN)

David Martin PhD

Bloom Burton

$14.15

Buy

-53.33%

Downside

Reiterated

10/21/25

Analysts Are Bullish on Top Healthcare Stocks: Nurix Therapeutics (NRIX), Viridian Therapeutics (VRDN)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Viridian Therapeutics

1 Month

xxx

Success Rate

9/16 ratings generated profit

Average Return

+8.43%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 56.25% of your transactions generating a profit, with an average return of +8.43% per trade.

3 Months

xxx

Success Rate

11/16 ratings generated profit

Average Return

+14.89%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 68.75% of your transactions generating a profit, with an average return of +14.89% per trade.

1 Year

Julian HarrisonBTIG

Success Rate

12/16 ratings generated profit

Average Return

+22.70%

reiterated a buy rating 2 months ago

Copying Julian Harrison's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +22.70% per trade.

2 Years

xxx

Success Rate

13/16 ratings generated profit

Average Return

+60.83%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 81.25% of your transactions generating a profit, with an average return of +60.83% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VRDN Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, VRDN has received 29 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. VRDN average Analyst price target in the past 3 months is 41.70.

Each month's total comprises the sum of three months' worth of ratings.

VRDN Financial Forecast

VRDN Earnings Forecast

Next quarter’s earnings estimate for VRDN is -$0.98 with a range of -$1.56 to -$0.45. The previous quarter’s EPS was -$0.34. VRDN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year VRDN has Performed in-line its overall industry.

VRDN Sales Forecast

Next quarter’s sales forecast for VRDN is $16.97M with a range of $0.00 to $55.08M. The previous quarter’s sales results were $70.57M. VRDN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year VRDN has Performed in-line its overall industry.

VRDN Stock Forecast FAQ

What is VRDN’s average 12-month price target, according to analysts?

Based on analyst ratings, Viridian Therapeutics’s 12-month average price target is 41.70.

What is VRDN’s upside potential, based on the analysts’ average price target?

Viridian Therapeutics has 37.49% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is VRDN a Buy, Sell or Hold?

Viridian Therapeutics has a consensus rating of Strong Buy which is based on 17 buy ratings, 0 hold ratings and 0 sell ratings.

What is Viridian Therapeutics’s price target?

The average price target for Viridian Therapeutics is 41.70. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $61.00 ,the lowest forecast is $14.15. The average price target represents 37.49% Increase from the current price of $30.33.

What do analysts say about Viridian Therapeutics?

Viridian Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.

How can I buy shares of VRDN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Viridian Therapeutics (VRDN) Stock Forecast & Price Target

VRDN Analyst Ratings

VRDN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Viridian Therapeutics

VRDN Analyst Recommendation Trends

VRDN Financial Forecast

VRDN Earnings Forecast

VRDN Sales Forecast

VRDN Stock Forecast FAQ

Detailed List of Analyst Forecasts